DUBLIN - Medtronic plc (NYSE:MDT), a global healthcare technology company, has announced the CE Mark approval for its advanced insulin delivery system, the MiniMed™ 780G, which is now paired with the new Simplera Sync™ sensor. This latest iteration of glucose monitoring technology requires no fingersticks or overtape and boasts a less than 10-second insertion time.
The MiniMed 780G system, known for its automatic glucose level adjustments every five minutes, will offer the Simplera Sync™ sensor in Europe starting with a limited release in spring 2024, followed by a phased commercial launch in the summer. The system is currently compatible with the Guardian™ 4 sensor.
Designed to ease the burden of carbohydrate counting and insulin dosing for diabetes patients, the MiniMed 780G system includes a Meal Detection™ feature aimed at reducing post-meal hyperglycemia. It also offers one of the lowest glucose target settings of any automated insulin delivery system, aiming to mirror the glucose levels of individuals without diabetes.
Robert Vigersky, M.D., Chief Medical Officer at Medtronic Diabetes, highlighted the system's ability to assist patients who may forget or miscalculate their insulin dosing. Que Dallara, EVP and President of Medtronic Diabetes, expressed pride in the system's widespread adoption in Europe and its performance, citing real-world data showing an average Time in Range of nearly 80%.
The MiniMed™ 780G system with Simplera Sync™ sensor is indicated for individuals aged 7 and older and is compatible with iOS and Android devices. However, the Simplera Sync™ sensor has not been approved by the FDA and is currently limited to investigational use in the U.S.
The information in this article is based on a press release statement from Medtronic plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.